Since 2002, Pharmidex has grown into a trusted partner in preclinical drug discovery and development, contributing to over 16,000 studies across therapeutic areas including CNS, immunology, oncology, respiratory and stroke. We’re proud to be AAALAC- and MHRA-accredited, providing high-quality GLP and GCP-compliant services that have supported clients across biotech, pharma, and academia worldwide. Our integrated expertise in Clinical Pathology, DMPK, ADMET, Pharmacokinetics, Toxicology and BBB penetration studies continues to shape the success of early-stage drug candidates. 💡 As we commemorate this milestone, we reflect on: ✔ The dedication of our exceptional team ✔ The trust and collaboration of our partners and clients ✔ Our continued mission to advance science and improve lives Here’s to 23 years of impact and many more to come!

Pharmidex is excited to support this incredible initiative, which welcomes 8 promising therapeutics companies at (or near) the pre-clinical stage. Over the next 8 weeks, they’ll sharpen their strategy using the Triple Chasm framework and gain access to a powerful mix of scientific, business, and communication support. During the launch, our very own Ash Alavijeh joined Prabhu Velusami, MD (Johnson & Johnson) and Daniel Marshall (MSD) in a panel discussion exploring trends and opportunities in the therapeutics landscape. It was a brilliant exchange of insights that inspired the cohort and sparked new conversations. As part of the Catalyser package, we’re proud to offer: 🔬 Complimentary CRO services from Pharmidex 🤖 AI innovation support with Asae Biotechnology Consulting 🎤 1:1 storytelling coaching with Kat Arney from First Create The Media Huge thanks to Hertfordshire Futures and Stevenage Bioscience Catalyst for driving this programme and for the opportunity to collaborate with such a forward-thinking ecosystem!